MarketCapExport financials
Apyx Medical Corporation (APYX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Apyx Medical Corporation APYX
$ 2.95
1.37%
Facebook
X
Telegram
Apyx Medical Corporation Balance Sheet 2025-2008 | APYX
Brief balance sheet overview of Apyx Medical Corporation
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets ended near their starting level at $66.8 million versus $68.7 million. This was preservation of scale rather than expansion.
Liabilities expanded faster than the asset base, +253.5% versus -2.7%. Debt-service capacity deserves attention.
The equity ratio is 21.8%, compared with 78.1% before. Low autonomy increases reliance on liabilities.
Net debt is $3.5 million, or 0.24x of equity. This is a conservative debt position.
Cash accounts for 47.5% of assets versus 44.9% initially. The change indicates the degree of financial flexibility.
Retained earnings are negative at -$89.1 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
Taken together, Apyx Medical Corporation's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.
Annual Balance Sheet Apyx Medical Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
3.52 M | 2.49 M | -10.1 M | -9.9 M | -30.7 M | -41.2 M | -57.7 M | -16.3 M | -7.12 M | -11.4 M | -8.49 M | -2.32 M | -4.67 M | -743 K | -664 K | - | - | - |
Long Term Debt |
34.8 M | 33.9 M | 33.2 M | 73 K | 18 K | - | - | 140 K | 2.6 M | 2.83 M | 3.07 M | 3.17 M | 3.18 M | 3.28 M | 3.63 M | - | - | - |
Long Term Debt Current |
407 K | 335 K | 347 K | 216 K | 122 K | 126 K | 108 K | - | 239 K | 239 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 1.1 M | 1.18 M | 140 K | 2.98 M | 3.62 M | 3.92 M | 16.4 M | 8.93 M | 3.37 M | 3.73 M | - | - | - |
Total Current Liabilities |
11.7 M | 10.7 M | 12.7 M | 11.8 M | 13.2 M | 9.15 M | 12.3 M | 8.61 M | 5.97 M | 5.27 M | 4.12 M | 3.77 M | 2.91 M | 1.92 M | 2.39 M | 1.8 M | - | - |
Total Liabilities |
52 M | 50.5 M | 52.3 M | 14 M | 14.7 M | 10.3 M | 13.5 M | 7.84 M | 8.96 M | 8.89 M | 8.04 M | 20.1 M | 11.8 M | 5.29 M | 6.12 M | 6.02 M | - | - |
Deferred Revenue |
- | - | 500 K | 900 K | 500 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-89.1 M | -77.9 M | -54.4 M | -35.7 M | -12.6 M | 2.62 M | 14.5 M | 35.5 M | -28.5 M | -23.4 M | -19.5 M | -27.8 M | -9.63 M | -2.64 M | -3.26 M | -3.37 M | - | - |
Total Assets |
66.8 M | 64.8 M | 79.2 M | 51.8 M | 68.7 M | 74.1 M | 84.7 M | 95.6 M | 31 M | 35.1 M | 31.4 M | 24.8 M | 33.2 M | 28.2 M | 28.2 M | 27.8 M | - | - |
Cash and Cash Equivalents |
31.7 M | 31.7 M | 43.7 M | 10.2 M | 30.9 M | 41.9 M | 58.8 M | 16.6 M | 9.95 M | 14.5 M | 11.8 M | 5.73 M | 7.92 M | 4.16 M | 4.88 M | 3.83 M | 2.16 M | 2.56 M |
Book Value |
14.8 M | 14.3 M | 26.9 M | 37.8 M | 54 M | 63.9 M | 71.3 M | 87.8 M | 22 M | 26.2 M | 23.4 M | 4.69 M | 21.3 M | 22.9 M | 22.1 M | 21.8 M | - | - |
Total Shareholders Equity |
14.5 M | 14.2 M | 26.7 M | 37.6 M | 53.7 M | 63.7 M | 71.3 M | 87.2 M | 22 M | 26.2 M | 23.4 M | 1.5 M | 19.1 M | 22.9 M | 22.1 M | 21.8 M | 21 M | 20.2 M |
All numbers in USD currency
Quarterly Balance Sheet Apyx Medical Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
35.3 M | 35.1 M | 34.6 M | 34.4 M | 34.1 M | 33.9 M | 33.9 M | 33.6 M | - | 33.2 M | 9.01 M | - | 8.78 M | 73 K | 78 K | 93 K | 13 K | 18 K | 22 K | 76 K | 107 K | 183 K | 183 K | 183 K | 183 K | 421 K | 421 K | 421 K | 421 K | - | - | 2.34 M | 2.4 M | 2.46 M | 2.46 M | 2.46 M | 2.46 M | 2.69 M | 2.69 M | 2.69 M | 2.69 M | 2.93 M | - | 140 K | 140 K | - | - | - | - | 3.18 M | 3.18 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
50 M | 49.9 M | 51.3 M | 50.7 M | 49.5 M | 50.5 M | 49.5 M | 50.5 M | - | 52.3 M | 25.9 M | - | 20.6 M | 14 M | 13.1 M | 13.3 M | 13.2 M | 14.7 M | 13.1 M | 11.9 M | 10.9 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 8.75 M | 7.72 M | 7.84 M | 7.84 M | 8.96 M | 8.96 M | 8.96 M | 8.96 M | 8.89 M | 8.89 M | 8.89 M | 8.89 M | 8.04 M | 8.04 M | 8.04 M | 8.04 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 5.29 M | 5.29 M | 5.29 M | 5.29 M | 6.12 M | 6.12 M | 6.12 M | 6.12 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 1.05 M | 853 K | - | - | 759 K | 533 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-94.5 M | -91.2 M | -87.8 M | -85.8 M | -82.1 M | -77.9 M | -73.3 M | -68.6 M | - | -54.4 M | -44.8 M | - | -39.2 M | -35.7 M | -29.7 M | -23.9 M | -18.5 M | -12.6 M | -10.5 M | -6.33 M | -2.28 M | 2.62 M | 2.62 M | 2.62 M | 2.62 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 34.2 M | 34.9 M | 35.5 M | 35.5 M | -28.5 M | -28.5 M | -28.5 M | -28.5 M | -23.4 M | -23.4 M | -23.4 M | -23.4 M | -19.5 M | -19.5 M | -19.5 M | -19.5 M | -27.8 M | -27.8 M | -27.8 M | -27.8 M | -9.63 M | -9.63 M | -9.63 M | -9.63 M | -2.64 M | -2.64 M | -2.64 M | -2.64 M | -3.26 M | -3.26 M | -3.26 M | -3.26 M |
Total Assets |
61.1 M | 63 M | 57.4 M | 58.2 M | 60.2 M | 64.8 M | 60.7 M | 65.4 M | - | 79.2 M | 59.4 M | - | 56.8 M | 51.8 M | 55.3 M | 59.5 M | 63 M | 68.7 M | 67.8 M | 69.6 M | 71.1 M | 74.1 M | 74.1 M | 74.1 M | 74.1 M | 84.7 M | 84.7 M | 84.7 M | 84.7 M | 95.9 M | 95.6 M | 95.6 M | 95.6 M | 31 M | 31 M | 31 M | 31 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M |
Cash and Cash Equivalents |
27.6 M | 31.1 M | 25.1 M | 29.3 M | 31 M | 31.7 M | 28 M | 32.7 M | - | 43.7 M | 22.1 M | 18.5 M | 16.3 M | 10.2 M | 14.8 M | 20.1 M | 26.2 M | 30.9 M | 30.9 M | 34.7 M | 39.5 M | 41.9 M | 41.9 M | 41.9 M | 41.9 M | 58.8 M | 58.8 M | 58.8 M | 58.8 M | 16.6 M | 16.5 M | 16.5 M | 16.5 M | 9.95 M | 9.95 M | 9.95 M | 9.95 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 5.73 M | 5.73 M | 5.73 M | 5.73 M | 7.92 M | 7.92 M | 7.92 M | 7.92 M | 4.16 M | 4.16 M | 4.16 M | 4.16 M | 4.88 M | 4.88 M | 4.88 M | 4.88 M |
Book Value |
11.1 M | 13.1 M | 6.08 M | 7.46 M | 10.6 M | 14.3 M | 11.2 M | 14.9 M | - | 26.9 M | 33.6 M | - | 36.2 M | 37.8 M | 42.2 M | 46.2 M | 49.8 M | 54 M | 54.7 M | 57.7 M | 60.2 M | 63.9 M | 63.9 M | 63.9 M | 63.9 M | 71.3 M | 71.3 M | 71.3 M | 71.3 M | 87.2 M | 87.9 M | 87.8 M | 87.8 M | 22 M | 22 M | 22 M | 22 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M | 4.69 M | 4.69 M | 4.69 M | 4.69 M | 21.3 M | 21.3 M | 21.3 M | 21.3 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M |
Total Shareholders Equity |
10.7 M | 12.8 M | 5.85 M | 7.25 M | 10.5 M | 14.2 M | 11.2 M | 14.9 M | 20.5 M | 26.7 M | 33.6 M | 36.7 M | 36.1 M | 37.6 M | 42.2 M | 45.9 M | 49.8 M | 53.7 M | 54.7 M | 57.7 M | 60 M | 63.7 M | 63.7 M | 63.7 M | 63.7 M | 71.3 M | 71.3 M | 71.3 M | 71.3 M | 87.2 M | 87.9 M | 87.8 M | 87.2 M | 22 M | 22 M | 22 M | 22 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Apyx Medical Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical devices
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B |  USA |
 |
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | USA |
 |
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | USA |
 |
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | USA |
 |
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | USA |
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | USA |
 |
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | Israel |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | USA |
 |
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | USA |
 |
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M |  Australia |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | USA |
 |
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | USA |
 |
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | USA |
 |
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |